biological source
rabbit
Quality Level
antibody form
affinity purified immunoglobulin
antibody product type
primary antibodies
clone
polyclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... TNFRSF10A(8797)
Specificity
Apoptosis, or programmed cell death, occurs during normal cellular diffferentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand of the TNF family through their death domain containing receptors, TNFR1 and Fas. A novel cell death receptor was recently identified by several groups independently and designated DR4 (for death receptor 4) (Pan et al. 1997). The ligand for this novel cell death receptor has been identified and termed TRAIL, which is a new member in TRF family. Therefore, DR4 is also called TRAIL receptor-1 (TRAIL-R1) (Schneider et al. 1997). DR4 is expresssed in most of human tissues including spleen, peripheral blood leukocytes, small intestine and thymus. Like TNFR1, Fas and DR3, DR4 mediates TRAIL induced apoptosis and NF-kB activation in many tissues and cells.
Immunogen
Epitope: C-terminus
Polyclonal antibody raised against a peptide corresponding to amino acids 427-445 at C-terminus of human DR4 mature protein.
Application
Detect DR4 using this Anti-DR4 Antibody, C-terminus validated for use in WB.
Research Category
Apoptosis & Cancer
Apoptosis & Cancer
Research Sub Category
Apoptosis - Additional
Apoptosis - Additional
Western blot: 1:500-1:1000
Whole cell lysate from HeLa cells can be used as a positive control and a 57 kDa band should be detected.
Optimal working dilutions must be determined by end user.
Whole cell lysate from HeLa cells can be used as a positive control and a 57 kDa band should be detected.
Optimal working dilutions must be determined by end user.
Physical form
Affinity purified immunoglobulin. Liquid in PBS containing 0.02% sodium azide.
Format: Purified
Storage and Stability
Maintain refrigerated at 2-8°C in undiluted aliquots for up to 12 months.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
V Pavet et al.
Cell death & disease, 5, e1043-e1043 (2014-02-01)
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/TNFSF10/Apo2L) holds promise for cancer therapy as it induces apoptosis in a large variety of cancer cells while exerting negligible toxicity in normal ones. However, TRAIL can also induce proliferative and migratory signaling in cancer
Sofie Hagelund et al.
Frontiers in cell and developmental biology, 10, 768579-768579 (2022-03-15)
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an important mediator of tumor immune surveillance. In addition, its potential to kill cancer cells without harming healthy cells led to the development of TRAIL receptor agonists, which however did not show the
Dmitri V Rozanov et al.
Molecular cancer therapeutics, 8(6), 1515-1525 (2009-06-11)
Successful cancer therapies aim to induce selective apoptosis in neoplastic cells. The current suboptimal efficiency and selectivity drugs have therapeutic limitations and induce concomitant side effects. Recently, novel cancer therapies based on the use of tumor necrosis factor-related apoptosis-inducing ligand
Anna Willms et al.
PloS one, 14(4), e0214847-e0214847 (2019-04-05)
Due to their ability to preferentially induce cell death in tumor cells, while sparing healthy cells, TNF-related apoptosis-inducing ligand (TRAIL) and agonistic anti-TRAIL-R1 or anti-TRAIL-R2-specific antibodies are under clinical investigations for cancer-treatment. However, TRAIL-Rs may also induce signaling pathways, which
Florent Dufour et al.
Oncotarget, 8(6), 9974-9985 (2017-01-01)
TRAIL induces selective tumor cell death through TRAIL-R1 and TRAIL-R2. Despite the fact that these receptors share high structural homologies, induction of apoptosis upon ER stress, cell autonomous motility and invasion have solely been described to occur through TRAIL-R2. Using
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service